#antifolate drugs

[medicomunicare]

TBC, the pandemic no one talks about in need for new solutions: unawareness or misleading?

TBC, the pandemic no one talks about in need for new solutions: unawareness or misleading?

Tuberculosis (TB) is an infectious disease caused by Mycobacterium tuberculosis also called Bacillus of Koch, from the name of the scientist who discovered it in 1882. There are 5 varieties: human, bovine, avian, murine, cold-blooded animals; of these only the first 2 are of importance in human pathology. Worldwide, TB is the leading infectious cause of morbidity and mortality in adults, and…

[doctorfoxtor]

post ain't long it's wrong, can't study till dawn? yawn

100 days of productivity

day 44 + 45

CVS/RS

rheumatoid pleural effusions closely mimic complicated parapneumonic effusion on analysis, w/ ph <7.2, marked ↑LDH and notably glucose <30 (in fact glucose >30 almost rules out rheumatoid effusion)

in afib, digoxin will slow ventricular rate but is unlikely to cardiovert the rhythm

itraconazole in ABPA causes a 50% reduction in steroid dose and 25% reduction in anti-aspergillus IgE, and either partial or complete resolution of CXR infiltrates or improvement in PFTs/exercise tolerance

TRALI can happen as early as 15 minutes into the transfusion apparently?????

mesothelioma is an abject death sentence. The most you can do for patients beyond stage 1 is chemotherapy (limited survival benefit with platinics), radiotherapy to biopsy/thoracoscopy tracts only and surgery (lung-sparing debulking ± pleurodesis for recurrent effusions; radical surgery has shown no survival benefit)

mild tachy + broad qRs in haemodynamically stable pt s/p PCI for MI → likely to be LBBB developing; watch and wait

CNS/Ophthal/Psych

PSP looks similar to parkinson's bc it affects the opposite pathway as parkinsons (striatonigral vs nigrostriatal)

the best response you can get from deep brain stimulation for parkinsons = the best response you got from medication; DBS will NOT add a greater response compared to maximum medical therapy

without any other information, parkinson's ssx w/ dementia WITHIN 1 year of onset, it's Lewy body dementia; if it's more than 1 year, it's parkinson's w/ 2° dementia

choroidal neovascularisation with NO OTHER fundal signs: wet mac degen > diabetic retinopathy

focal dystonias are better treated with botox than with medication

SAH is unlikely to cause cranial nerve palsies other than III and maybe VI; pituitary apoplexy presents similarly with very severe headache/projectile vomiting/AMS, while affecting nerves III, IV, V-1 and VI

MS relapse: 500 mg PO or 1 g IV methylpred x5 days

there is no difference in risk of progression to Korsakoff when Wernicke is treated w/ glucose first vs w/ thiamine first

Endocrine/Repro

hyperaldosteronism: hyperplasia > adenoma

acute alcohol consumption can trigger hypoglycaemic events as the liver uses up NAD+ for each step of the alcohol detox pathway, where NAD+ is an important cofactor for the malate-oxalate shuttle used in gluconeogenesis

cinacalcet's major indication is hyperparathyroidism taht can't be corrected w/ surgery (eg, unfit pts)

Rheum/Derm/Immuno

topical steroid potency: hydrocortisone < clobetasol butyrate, betamethasone valerate low-dose < betamethasone valerate high-dose, fluticasone propionate < clobetasol propionate

onycholysis: trauma, tinea (infections), thyrotoxicosis, tetracyclines

pseudoxanthoma elasticum is assoc w/ mitral prolapse, renovascular htn, PVD, CAD, GIT bleeds and retinal vessel abnormalities

IgE values are normally distributed, so about 2.5% of the pop has raised IgE and 2.5% has reduced

s/p parathyroidectomy → acute drop in PTH → bones that are used to high levels of PTH experience a relative hypoPTHism → ↑blastic ↓clastic activity → acute bony uptake of calcium, PO4 and importantly magnesium = hungry bone syndrome (replace calcium and magnesium!)

carpal tunnel pain can radiate retrogradely to the forearm and sometimes even the arm

periarticular osteoporosis → RA

punched out erosions in juxtaarticular bone → gout

GIT

Peutz-Jeghers: small bowel hamartomas → intussusception, colorectal cancer, pigmented lesions (classically perioral/mucosal, but also palms/soles)

pernicious anaemia: parietal cell Abs (common) > intrinsic factor Abs (specific)

haemochromatosis: venesection → keep ferritin <50 and transferrin sat <50%

passing stools frequently, elevated inflammatory markers, ↑faecal calprotectin, PPI but not in demographic for IBD → take a colonoscopy and biopsy, this is probably microscopic colitis (and PPIs can trigger at any age)

liver biopsy is not indicated for Gilbert's—it is sufficient to do routine CBCs/LFTs w/ bilirubin analysis

pancreolauryl (fluorescein dilaurate) is quite nonspecific and will not pinpoint the exact pancreatic disease

hep A can be precided by short diarrhoeal illness`

in an IBD (esp UC) pt who comes >10 yrs after initial symptoms with recent change in bowel habits, offer urgent colonoscopy to r/o ca colon BEFORE starting on treatment

Onc/Haem

MTX + antifolate antibiotics: makes sense not to give them together—they can cause fulminant marrow failure

leukaemia can very rarely lead to acute painful scrotal swelling

5q- syndrome = myelodysplasia, but with thrombocytosis; diff from essential thrombocythaemia by anaemia with normal reticulocyte count and leukopaenia in the former

radiotherapy is a primary modality of tx in retinal, CNS, skin, oesophageal, cervical, vaginal and prostatic tumours; it is adjuvant in all other tumours

the commonest presentations of CMV s/p txp are pneumonia or pulmonary infiltrates

Renal/Biochem

SIADH causing drugs - SIADH Causes Poor Voiding: Sedatives (barbiturates), Indomethacin (NSAIDs), Antidepressants (TCAs/SSRIs), thiazide Diuretics, 1st gen antiHistamines, Cyclophosphamide/antiConvulsants, 1st gen antiPsychotics, Vinca alkaloids

malaria: irreversible nephrosis (esp memb or FSGS) > nephritis

2° syphilis: reversible nephritis > nephrosis

even if the patient doesn't qualify for ACEis/ARBs for HTN, give them first-line anyway if concomitant renal disease

kidney size difference >1 cm is significant

for drugs that will be dialysed out on dialysis days, dose them immediately after dialysis on those days

only urge incontinence is not primarily managed with pelvic floor exercises

Pharm/Toxo

valproate ADRs - VALPROATE: Vomiting, Alopecia/Anorexia, Liver tox, Pancreatitis/PCOS, Redistributed fat (weight gain/lipodystrophy), Oedema, hyperAmmonaemia/Ataxia, Tremor/Thrombocytopaenia, Enzyme inhibitor

opioid withdrawal: methadone is the best single tx and avoids needing to give multiple drugs to cover ssx (eg, clonidine + dextromethorphan + loperamide)

aminoglycosides preferentially affect proximal tubular cells

the classic pattern of symptoms in both cotton workers and workers at factories that process nitrates is that of 'Monday disease'

toxicities for which measuring the blood levels is indicated - SLIME TiPP: Salicylates, Lithium, Iron, Methanol, Ethylene glycol, Theophylline, Paraquat, Paracetamol

amphetamine tox → hyponatraemia due to water retention, worsened by the excessive thirst; hyperkalaemia → rhabdo; hypokalaemia not seen because amphetamines tho sympathetomimetic do not have affinity for the β2 receptor like cocaine does

[bhandvalkar94]

Global Antibiotic Resistance Market Growth, Current Status and Future Scenario of Industry Surveyed in New Research Report 2021-2030

Absolute Markets Insights has announced a statistical data to its extensive repository titled Antibiotic Resistance market. The study comprises of different segments and sub-segments such as type, size, applications, and end-users. One of the many distinctive features of the report is it provides an analytical study of the global Antibiotic Resistance market based on various growth influencing factors. Primary and secondary research techniques have also been used by analysts of the report to study the market. The study also uses information on widespread global regions such as North America, Latin America, Europe, Asia-Pacific, Africa, and India in order to get a better understanding of the competitive landscape. The research report extensively focuses on market size, pricing structures, and shares. The current development patterns of various successful industries have also been mentioned in order to understand effective business strategies.

Vendor Profiling: Antibiotic Resistance Market: Allergan Pharma Co., GlaxoSmithKline PLC., Johnson & Johnson Services Inc., MELINTA THERAPEUTICS - THE ANTIBIOTICS COMPANY, Merck & Co. Inc., Mylan N.V., Nabriva Therapeutics PLC, Otsuka Novel Products GmbH, Pfizer Inc., and Sandoz AG amongst others.

For more information about this report visit: https://www.absolutemarketsinsights.com/reports/Antibiotic-Resistance-Market-2021---2029-876

Key Findings of the Report:

The global antibiotic resistance market was valued at US$ 8417.36 Mn in 2020 growing at a CAGR of 4% over the forecast period (2021 – 2030).

The carbapenem-resistant enterobacteriaceae (CRE) category in the global antibiotic resistance market held the larger market share in 2020. Carbapenem-resistant enterobacteriaceae (CRE) are a family of bacteria that are very difficult to treat due to their highly resistant nature towards antibiotics. They have a reputation of adapting to different types of antibiotic treatments and develop resistance towards them.

The complicated urinary tract infections (cUTI) category in the global antibiotic resistance market held the larger share in 2020. Urinary tract infections (UTIs) are considered to be one of the most common types of infections. According to studies, at least one in two women and one in 10 men experience UTI in their life period.

Antifolates segment occupied the largest market share in the global antibiotic resistance market in 2020. Antifolate drugs are helpful in the treatment of communicable and infectious diseases such as malaria. Many bacteria and viruses that have developed antibiotic resistance spread diseases similar to malaria, such as dengue and other mosquito-borne diseases.

Global Antibiotic Resistance Market: Research Scope

By Resistant Bacteria Type

Pseudomonas Aeruginosa

Clostridioides difficile (C. difficile)

Carbapenem-resistant Enterobacteriaceae (CRE)

Streptococcus pneumoniae (S. pneumoniae)

Acinetobacter

Vancomycin-resistant Enterococci (VRE)

Mycobacterium Tuberculosis (TB)

Neisseria gonorrhoeae (N. gonorrhoeae)

Others

By Disease Indication

Complicated Urinary Tract Infections (cUTI)

Complicated Intra-Abdominal Infections (cIAI)

Community-Acquired Bacterial Pneumonia (CABP)

Acute Skin and Skin Structure Infections (ABSSSI)

Multidrug-Resistant (MDR) and Pulmonary Extensively Drug Resistant (XDR) Tuberculosis (TB) (MDR-TB and XDR-TB)

Sepsis

Clostridium Difficile (C. difficile) Infections

Others

By Drug Class

Antimycobacterials

Fluoroquinolones

Oxazolidinones

Tetracyclines

Penicillins

Antifolates

Combination Treatment

Others

By Route of Administration

Oral

Topical

Intramuscular

Intravenous (IV)

By End Use

Home Care

Healthcare Facilities

Others

By Region

North America

Europe

Asia Pacific

Middle East and Africa

Latin America

Contact Us:

Company: Absolute Markets Insights

Email id: sales@absolutemarketsinsights.com

Phone: +91-740-024-2424

Contact Name: Shreyas Tanna

Website: https://www.absolutemarketsinsights.com/

[mariebenz]

Anti-Folate Drugs Might Prevent COVID-19 (and other viruses) From Taking Over Cell Metabolism

MedicalResearch.com Interview with: Benjamin E. Gewurz MD, PhD Broad Institute of MIT and Harvard, Cambridge, Division of Infectious Disease, Department of Medicine, Brigham and Women’s Hospital, Department of Microbiology, Harvard Medical School Boston, MA  MedicalResearch.com: What is the background for this study? Response: When the Covid-19 virus infects cells, it takes over and redirects our cells resources towards the projection of virus building blocks and new viruses.  Building blocks include large amounts of RNAs that encode for the viral proteins, much as the mRNA vaccines direct our bodies to make the spike protein. We wondered how the virus changes cell metabolism in order to support the synthesis of vast amounts of viral RNAs within hours of infection. MedicalResearch.com: What are the main findings? Response: We identified that SARS-CoV-2 coronavirus that causes COVID19 increases the ability of infected cells to synthesize nucleotide building blocks that can be used for viral RNA synthesis. Activity of a folate metabolism pathway normally used by our cells to make DNA and RNA nucleotides becomes more active. Based on this observation, we tested whether antifolate drugs, including methotrexate could suppress the production of coronavirus mRNA, protein and new viruses.  Read the full article

[insightsmarket]

Malaria Drugs Market Research with COVID-19 | Cipla, Guilin Pharmaceutical, IPCA Laboratories, GlaxoSmithKline, Mylan Labs, Roche, Novartis, Sanofi Aventis, Ajanta Pharma, Kunming Pharmaceutical

The pandemic of Coronavirus (COVID-19) has affected every aspect of life globally. This has brought along several changes in market conditions. The rapidly changing market scenario and initial and future assessment of the impact is covered in the report. It covers the entire market with an in-depth study on revenue growth and profitability. The report also delivers on key players along with strategic standpoint pertaining to price and promotion. Our sample reports are free of charge and contain multiple sections of the report including the market size and forecast, drivers, challenges, trends, and more. Get Exclusive PDF Sample Copy of This Report @ www.researchallied.com/request-sample/10506-malaria-drugs-market With an all-round approach for data accumulation, the market scenarios comprise major players, cost and pricing operating in the specific geography/ies. Statistical surveying used are SWOT analysis, PESTLE analysis, predictive analysis, and real-time analytics. Graphs are clearly used to support the data format for clear understanding of facts and figures. Top Companies in this report includes: Cipla, Guilin Pharmaceutical, IPCA Laboratories, GlaxoSmithKline, Mylan Labs, Roche, Novartis, Sanofi Aventis, Ajanta Pharma, Kunming Pharmaceutical. Major Type included in the report are: Aryl Aminoalcohol Compounds, Antifolate Compounds, Artemisinin Compounds. Major Applications included in the report are: Prevention, Treatment, Other. !!! Limited Time DISCOUNT Available!!! Get Your Copy at Discounted Price@ www.researchallied.com/check-discount/10506-malaria-drugs-market About Malaria Drugs Industry The overviews, SWOT analysis and strategies of each vendor in the Malaria Drugs market provide understanding about the market forces and how those can be exploited to create future opportunities. Important application areas of Malaria Drugs are also assessed on the basis of their performance. Market predictions along with the statistical nuances presented in the report render an insightful view of the Malaria Drugs market. The market study on Global Malaria Drugs Market 2020 report studies present as well as future aspects of the Malaria Drugs Market primarily based upon factors on which the companies participate in the market growth, key trends and segmentation analysis. Manufacturing Analysis Malaria Drugs Market Manufacturing process for the Malaria Drugs is studied in this section. It includes through analysis of Key Raw Materials, Key Suppliers of Raw Materials, Price Trend of Key Raw Materials, cost of Raw Materials & Labor Cost, Manufacturing Process Analysis of Malaria Drugs market Buy Full Copy Global Keyword Report 2020-2026 @ www.researchallied.com/placeorder?report=10506-malaria-drugs-market&type=su Marketing Strategy Analysis, Distributors/Traders Analysis of Malaria Drugs Market Various marketing channels like direct and indirect marketing are portrayed in Malaria Drugs market report. Important marketing strategical data, Marketing Channel Development Trend, Pricing Strategy, Market Positioning, Target Client Brand Strategy and Distributors/Traders List. To understand the global Keyword market dynamics, the market is analyzed across major global regions and countries. Stats and Reports provides customized specific regional and country-wise analysis of the key geographical regions as follows: North America: USA, Canada, Mexico Latin America: Argentina, Chile, Brazil, Peru, and Rest of Latin America Europe: UK., Germany, Spain, Italy, and Rest of EU Asia-Pacific: India, China, Japan, South Korea, Australia, and Rest of APAC Middle East & Africa: Saudi Arabia, South Africa, U.A.E., and Rest of MEA To read more about the report @ www.researchallied.com/report/10506-malaria-drugs-market/ Thank you for reading our report. The report can be customized as per clients needs. For further inquiries, please connect with us. We will ensure the report is tailored according to your requirements. About Us Research Allied is a global market research and consulting service provider specialized in offering wide range of business solutions to their clients including market research reports, primary and secondary research, demand forecasting services, focus group analysis and other services. We understand that how data is important in today's competitive environment and thus, we have collaborated with industry's leading research providers who works continuously to meet the ever-growing demand for market research reports throughout the year. Contact: Research Allied Mangalam Chamber, Office No-16, Paud Road Sankalp Society, Kothrud, Pune, Maharashtra 411038 Phone: +1 650-646-3808 Email: sales@researchallied.com Website: https://www.researchallied.com Follow Us on: LinkedIN | Twitter |

[shradhaattumb]

Global Drugs for Malaria Market Updates, News and Data 2020-2025

Summary

A new market study, titled “Global Drugs for Malaria Market Growth 2020-2025” has been featured on WiseGuyReports.

According to this study, over the next five years the Drugs for Malaria market will register a xx%% CAGR in terms of revenue, the global market size will reach $ xx million by 2025, from $ xx million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Drugs for Malaria business, shared in Chapter 3.

This report presents a comprehensive overview, market shares, and growth opportunities of Drugs for Malaria market by product type, application, key manufacturers and key regions and countries.

ALSO READ:  https://www.einpresswire.com/article/527191990/global-drugs-for-malaria-market-2020-industry-analysis-size-share-growth-trends-forecast-to-2026

This study specially analyses the impact of Covid-19 outbreak on the Drugs for Malaria, covering the supply chain analysis, impact assessment to the Drugs for Malaria market size growth rate in several scenarios, and the measures to be undertaken by Drugs for Malaria companies in response to the COVID-19 epidemic.

Segmentation by type: breakdown data from 2015 to 2020, in Section 2.3; and forecast to 2025 in section 11.7. Aryl Aminoalcohol Compounds Antifolate Compounds Artemisinin Compounds

Segmentation by application: breakdown data from 2015 to 2020, in Section 2.4; and forecast to 2024 in section 11.8. Prevention Treatment Other

This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8. Americas United States Canada Mexico Brazil APAC China Japan Korea Southeast Asia India Australia Europe Germany France UK Italy Russia Middle East & Africa Egypt South Africa Israel Turkey GCC Countries

The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3. Cipla Guilin Pharmaceutical GlaxoSmithKline Mylan Labs IPCA Laboratories Sanofi Aventis Roche Ajanta Pharma Novartis

In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.

Research objectives To study and analyze the global Drugs for Malaria consumption (value & volume) by key regions/countries, type and application, history data from 2015 to 2019, and forecast to 2025. To understand the structure of Drugs for Malaria market by identifying its various subsegments. Focuses on the key global Drugs for Malaria manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years. To analyze the Drugs for Malaria with respect to individual growth trends, future prospects, and their contribution to the total market. To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks). To project the consumption of Drugs for Malaria submarkets, with respect to key regions (along with their respective key countries). To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market. To strategically profile the key players and comprehensively analyze their growth strategies.

FOR MORE DETAILS – https://www.wiseguyreports.com/reports/4965421-global-drugs-for-malaria-market-growth-2020-2025

  About Us:

Wise Guy Reports is part of the Wise Guy Research Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe.                

 Contact Us:

NORAH TRENT                                                      

sales@wiseguyreports.com       

Ph: +162-825-80070 (US)                          

Ph: +44 203 500 2763 (UK)      

[cancertame3]

What is Chemotherapy?

Chemotherapy (often abbreviated to chemo and sometimes CTX or CTx) is a type of cancer treatment that uses one or more chemotherapeutic agents (anti-cancer drugs) to destroy rapidly growing cells in the body, such as cancer cells which grow and divide faster than other cells in the body. Chemotherapy is primarily used to lower the total number of cancerous cells in the body and shrink tumour size. In the case of advanced stage cancers, chemotherapy may help to relieve pain.

History of Chemotherapy

The use of chemotherapy to treat cancer began at the start of the 20th century. Several attempts were made to narrow down the chemicals that might affect the disease by developing various methods to screen chemicals using transplantable tumours in the rodents. Chemotherapy was first coined as a word in the early 1900s by a German chemist Paul Ehrlich, who defined it as the use of chemicals to treat disease[1].

During World War I, mustard gas was used as a chemical warfare agent. It was discovered that the gas was a potent suppressor of haematopoiesis (blood production). Similarly, nitrogen mustards were studied during World War II after the effects of an accidental spill of sulphur mustards on troops from a bombed ship in Bari Harbour, Italy[2]. This incident led to an observation that both bone marrow and lymph nodes were marked depleted in those who were exposed to mustard gas. It was believed that an agent which could damage the rapidly growing white blood cells might have a similar effect on cancer. The first chemotherapeutic drug developed from this research was Mustine (chlormethine, sold under the brand name of Mustargen). Sidney Farber collaborated with Lederle Laboratories to develop a series of folic acid analogues. These compounds included aminopterin and amethopterin, now known as methotrexate. Farber tested these antifolate compounds in children with leukaemia and in 1948, the results of these tests showed unquestionable remissions[3]. Farber is regarded as the father of modern chemotherapy.

In the mid-1950s, Charles Heidelberger and his colleagues developed a drug that was aimed at non-hematologic cancers[4]. Heidelberger “targeted” a biochemical pathway by attaching a fluorine atom to the 5-position of the uracil pyrimidine base which resulted in the synthesis of fluoropyrimidine 5-fluorouracil (5-FU). This agent was found to have broad-spectrum activity against a range of solid tumours and to this day, remains the cornerstone for the treatment of colorectal cancer. This agent represents the very first example of targeted therapy which has now become a focus in current cancer drug development, although the target, in this case, was a biochemical pathway instead of a molecular pathway.

Methods

There are a number of methods in the administration of chemotherapeutic drugs used today. Chemotherapy may be given with a curative intent or it may aim to prolong life or as palliative care. Induction chemotherapy is considered as the first line of treatment of cancer with a chemotherapeutic drug. It is usually given with curative intent.

Combined modality chemotherapy is the use of drugs along with other cancer treatments like surgery, radiation therapy, ayurvedic treatment (such as Cancertame), homeotherapy treatment etc

Combination chemotherapy involves treating a person with a number of different drugs simultaneously. This is one of the most used methods in chemotherapy as it minimises the chances of resistance developing to any one agent. For the treatment of bladder cancer, for example, a combination of Methotrexate, vincristine, doxorubicin, cisplatin is used

Neoadjuvant chemotherapy is given with an aim to shrink the tumour prior to principal treatment such as radiotherapy or surgery[5]

Adjuvant chemotherapy is given after principal treatment. It is an effective treatment if the cancerous cells have spread to other parts of the body

Types of Chemotherapy

1) Alkylating agents are the oldest group of chemotherapeutics in use today. There are several types of alkylating agents used in chemotherapy treatments such as:

Mustard gas derivatives -  Mechlorethamine, Cyclophosphamide, Chlorambucil, Melphalan, and Ifosfamide

Ethylenimines - Thiotepa and Hexamethylmelamine

Alkyl sulfonates - Busulfan

Hydrazines and Triazines - Altretamine, Procarbazine, Dacarbazine and Temozolomide

Nitrosoureas - Carmustine, Lomustine and Streptozocin.  Nitrosoureas are unique because, unlike most types of chemo treatments, they can cross the blood-brain barrier.  They can be useful in treating brain tumours.

Metal salts - Carboplatin, Cisplatin, and Oxaliplatin

2) Antimetabolites are a group of molecules which impede DNA and RNA synthesis such as:

Folic acid antagonist - Methotrexate

Pyrimidine antagonist - 5-Fluorouracil, Floxuridine, Cytarabine, Capecitabine, and Gemcitabine

Purine antagonist - 6-Mercaptopurine and 6-Thioguanine

Adenosine deaminase inhibitor - Cladribine, Fludarabine, Nelarabine and Pentostatin

3) Topoisomerase Inhibitors are drugs which interfere with the action of topoisomerase enzymes which control the manipulation of the structure of DNA necessary for replication

Topoisomerase I inhibitors - Irinotecan, topotecan

Topoisomerase II inhibitors - Amsacrine, etoposide, etoposide phosphate, teniposide

4) Plant Alkaloids are chemotherapy treatments derived from certain types of plants.

Vinca alkaloids (made from Catharanthus roseus) - Vincristine, Vinblastine and Vinorelbine

Taxanes (made from Taxus) - Paclitaxel and Docetaxel

Podophyllotoxins (derived from may apple plant) - Etoposide and Tenisopide

Camptothecin analogues (derived from camptothecin acuminate) - Irinotecan and Topotecan

Side Effects of Chemotherapy

Chemotherapy can produce adverse side effects that range from mild to severe, depending on the type and extent of the treatment. Some people may experience adverse to a few side effects which vary from person to person and the stage of cancer. Toxicities related to chemotherapy can occur acutely within hours to days, or chronically, after weeks to years[6].

Some common side effects of chemotherapy are:

Nausea and vomiting

Hair loss

Skin changes

Nail changes

Fatigue

Hearing impairment

Infections

Bleeding problems

Anaemia

Loss of appetite

Bowel problems

Cognitive and mental health problems

Luckily, due to advancement in medical research, ayurvedic drugs such as Cancertame when taken along with chemotherapy can minimize such side effects providing for a better integrative treatment for cancer patients.

New Treatment Management Protocols

The practice of utilizing chemotherapy for the treatment of cancer began in the 1940s and still remains a fundamental treatment for various types of cancer. Given the poisonous origin of chemotherapy, patients receiving these treatments experienced some severe side effects which create a demand for new treatment management protocols. Research over the past 30 years has led to the discovery of medications aimed at reducing the side effects of chemotherapy.

Targeted therapies became more popular and are one of the major focus of current cancer drug development. Although the very first use of this method was done back in the 1950s, this therapy aims for the specific targets that are specific to cancer cells and do not occur or are rare in healthy cells

Electrochemotherapy is a combined treatment in which an injection of a chemotherapeutic drug is followed by the application of high-voltage electric pulses to the tumour. This treatment enables the chemotherapeutic drugs, which cannot or hardly go through the membrane of cells, to enter cancer cells

Hyperthermia therapy is a heat treatment of cancer that can be very effective if combined with chemotherapy. The heat can be applied locally to the tumour site, which will dilate blood vessels to the tumour, allowing the more chemotherapeutic medication to enter the tumour. The tumour cell membrane will become more porous which will further allow more of the chemotherapeutic medicine to enter the tumour cell

Other medications such as Cancertame can also help to reduce the side effects of chemotherapy by enhancing the immune system of the body, and also helps to fight the growth of cancer by inducing apoptosis (cell death) and inhibiting tumour angiogenesis.

References

DeVita VT, Chu E (November 2008). "A history of cancer chemotherapy". Cancer Research. 68 (21): 8643–53

Krumbhaar EB, Krumbhaar HD. The blood and bone marrow in yellow gas (mustard gas) poisoning. Changes produced in bone marrow in fatal cases. J Med Res 1919; 40: 497–508

Farber S, Diamond LK, Mercer RD, et al. Temporary remissions in acute leukaemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid (aminopterin). N Eng. J Med 1948; 238: 787–93

Heidelberger C, Chaudhuari NK, Danenberg P, et al. Fluorinated pyrimidines. A new class of tumor inhibitory compounds. Nature 1957; 179: 663–6

Rachel Airley (2009). Cancer chemotherapy. Wiley-Blackwell

https://www.cancertame.com/in/article.php?title=What%20is%20Chemotherapy?&article_id=VmtkNFUxSXdjM2xYYmxaV1ltMTRjbFpxUmxaUFVUMDk=

https://www.cancertame.com

[bhandvalkar94]

Global Antibiotic Resistance Market to Grow at 4% CAGR during 2021-2029

When microbes evolve biological mechanisms that can protect them from elimination by antimicrobial, the danger of antimicrobial resistance (AMR) is visible. AMR are drug-resistant pathogens whose spread is a growing public health concern in many countries. The growth of resistant bacteria usually happens due to overuse of antibiotics, or due to their use being different from what has been prescribed. This renders antibiotics less effective or ineffective. It is believed that by 2050, AMR infections may cause 10 million deaths annually. Increase in hospitalizations and increasing use of antibiotics in COVID-19 treatment are expected to further exacerbate AMR. Hence, the market for antibiotic resistance research and medicines useful for treatment is expected accelerate in the near future.

Tuberculosis (TB) is one of the most dangerous infectious diseases from a single infectious agent and its virus has developed significant antibiotic resistance in the modern times. Multidrug-resistant TB (MDR-TB) is considered a global public health emergency by the World Health Organization. According to 2017 estimates, 465,000 cases of TB were estimated worldwide. 38% people were eligible for MDR/Rifampicin-resistant (RR)-TB. 57% of MDR/RR-TB cases received successful treatment. Mylan has also secured approval from Drugs Controller General of India (DCGI) for Pretomanid, which is useful for treatment for highly drug-resistant forms of tuberculosis. Johnson & Johnson has been in the business of developing and responsibly deploying innovative technologies and treatments to combat the growing threat of AMR on multiple fronts.

Request a sample Copy@

https://www.absolutemarketsinsights.com/request_sample.php?id=876

The major factor driving the growth of global antibiotic resistance market is the growing prevalence of hospital-acquired infections. Antibiotic resistant bacteria can spread from person to person in the community. Implementing precautionary infection control procedures can minimize spread of such bacteria in hospitals. From person to person, usually this infection spreads from contact with either contaminated hands of hospital staff, or contaminated surfaces such as door handles, over-bed tables and call bells. Sometimes it also spreads due to contact with contaminated equipment that includes stethoscopes and blood pressure cuffs.

Strategic investments coupled with favorable initiatives by regulatory authorities showcases significant opportunities for the growth of global antibiotic resistance market over the period of next eight years. The Food and Drug Administration (FDA) of the United States of America (USA) and the Centers for Disease Control (CDC) in USA have launched several initiatives to help address antibiotic resistance. FDA is also encouraging new research into effective diagnostic tests, antibiotic regimens, and vaccines. Under qualified infectious disease product (QIDP) program, which is meant to encourage antibiotic development, FDA has also approved new and innovative antibiotics for resistant infections. Such antibiotics include Arikayce (amikacin liposome inhalation suspension), Baxdela (delafloxacin), Nuzyra (omadacycline), Pretomanid, Recarbrio (cilastatin, imipenem, & relebactam), Xerava (eravacycline), and Xepi (ozenoxacin).

The different variants of the coronoavirus has had severe impact on patients. Increased dosage of antibiotics are being prescribed to COVID patients who developed co-infections (bacterial with coronavirus). Increased investments into research and development initiatives towards adequate treatment of the same is anticipated to propel the growth of global antibiotic resistance market over the forecast period.

Enquiry Before Buying@

https://www.absolutemarketsinsights.com/enquiry_before_buying.php?id=876

 Key Findings of the Report:

·         The global antibiotic resistance market was valued at US$ 8417.36 Mn in 2020 growing at a CAGR of 4% over the forecast period (2021 – 2029).

·         The carbapenem-resistant enterobacteriaceae (CRE) category in the global antibiotic resistance market held the larger market share in 2020. Carbapenem-resistant enterobacteriaceae (CRE) are a family of bacteria that are very difficult to treat due to their highly resistant nature towards antibiotics. They have a reputation of adapting to different types of antibiotic treatments and develop resistance towards them.

·         The complicated urinary tract infections (cUTI) category in the global antibiotic resistance market held the larger share in 2020. Urinary tract infections (UTIs) are considered to be one of the most common types of infections. According to studies, at least one in two women and one in 10 men experience UTI in their life period.

·         Antifolates segment occupied the largest market share in the global antibiotic resistance market in 2020. Antifolate drugs are helpful in the treatment of communicable and infectious diseases such as malaria. Many bacteria and viruses that have developed antibiotic resistance spread diseases similar to malaria, such as dengue and other mosquito-borne diseases.

·         In 2020, North America dominated the global antibiotic resistance market. Availability of advanced medical sector, increasing prevalence of infectious diseases, presence of major market players, numerous drug launches in the market, and rising growth in the pharmaceutical sector amongst other factors have contributed towards the region’s highest share. Infectious Diseases Society of America (IDSA) has approved the use of many new drugs that are expected to offer successful treatment against bacteria and viruses that have developed antibiotic resistance.

·         Some of the major players operating in the global antibiotic resistance market are Allergan Pharma Co., GlaxoSmithKline PLC., Johnson & Johnson Services Inc., MELINTA THERAPEUTICS - THE ANTIBIOTICS COMPANY, Merck & Co. Inc., Mylan N.V., Nabriva Therapeutics PLC, Otsuka Novel Products GmbH, Pfizer Inc., and Sandoz AG amongst others.

Request for Customization@

https://www.absolutemarketsinsights.com/request_for_customization.php?id=876

Global Antibiotic Resistance Market:

·         By Resistant Bacteria Type

o   Pseudomonas Aeruginosa

o   Clostridioides difficile (C. difficile)

o   Carbapenem-resistant Enterobacteriaceae (CRE)

o   Streptococcus pneumoniae (S. pneumoniae)

o   Acinetobacter

o   Vancomycin-resistant Enterococci (VRE)

o   Mycobacterium Tuberculosis (TB)

o   Neisseria gonorrhoeae (N. gonorrhoeae)

o   Others

 ·         By Disease Indication

o   Complicated Urinary Tract Infections (cUTI)

o   Complicated Intra-Abdominal Infections (cIAI)

o   Community-Acquired Bacterial Pneumonia (CABP)

o   Acute Skin and Skin Structure Infections (ABSSSI)

o   Multidrug-Resistant (MDR) and Pulmonary Extensively Drug Resistant (XDR) Tuberculosis (TB) (MDR-TB and XDR-TB)

o   Sepsis

o   Clostridium Difficile (C. difficile) Infections

o   Others

 ·         By Drug Class

o   Antimycobacterials

o   Fluoroquinolones

o   Oxazolidinones

o   Tetracyclines

o   Penicillins

o   Antifolates

o   Combination Treatment

o   Others

 ·         By Route of Administration

o   Oral

o   Topical

o   Intramuscular

o   Intravenous (IV)

 ·         By End Use

o   Home Care

o   Healthcare Facilities

o   Others

 ·         By Region

o   North America

§  U.S.

§  Canada

§  Mexico

§  Rest of North America

o   Europe

§  France

§  The UK

§  Spain

§  Germany

§  Italy

§  Nordic Countries

·         Denmark

·         Finland

·         Iceland

·         Sweden

·         Norway

§  Benelux Union

·         Belgium

·         The Netherlands

·         Luxembourg

§  Rest of Europe

o   Asia Pacific

§  China

§  Japan

§  India

§  New Zealand

§  Australia

§  South Korea

§  Southeast Asia

·         Indonesia

·         Thailand

·         Malaysia

·         Singapore

·         Rest of Southeast Asia

§  Rest of Asia Pacific

o   Middle East & Africa

§  Saudi Arabia

§  UAE

§  Egypt

§  Kuwait

§  South Africa

§  Rest of Middle East & Africa

o   Latin America

§  Brazil

§  Argentina

§  Rest of Latin America

For More Information Click@ https://www.absolutemarketsinsights.com/reports/Antibiotic-Resistance-Market-2021---2029-876

About Us: Absolute Markets Insights assists in providing accurate and latest trends related to consumer demand, consumer behavior, sales, and growth opportunities, for the better understanding of the market, thus helping in product designing, featuring, and demanding forecasts. Our experts provide you the end-products that can provide transparency, actionable data, cross-channel deployment program, performance, accurate testing capabilities and the ability to promote ongoing optimization. From the in-depth analysis and segregation, we serve our clients to fulfill their immediate as well as ongoing research requirements. Minute analysis impact large decisions and thereby the source of business intelligence (BI) plays an important role, which keeps us upgraded with current and upcoming market scenarios.

Contact Us:

Company: Absolute Markets Insights Email id: sales@absolutemarketsinsights.com  Phone: +91-740-024-2424 Contact Name: Shreyas Tanna The Work Lab,Model Colony, Shivajinagar, Pune, MH, 411016 Website: https://www.absolutemarketsinsights.com/

[techscimarketresearch]

Central Nervous System Therapeutics Market to grow at a Significant Rate During the Forecast Period | TechSci Research

Demand for effective therapeutics for treatment of CNS is a driving factor for the growth of Global Central Nervous System Therapeutics Market in forecast period.

 According to TechSci Research report, “Global Central Nervous System Therapeutics Market By Drug Class (Analgesics, Anesthetics, Anticonvulsants, Antiepileptics, Anti-Parkinson Agents, Others) By Application (Neurovascular Diseases, Mental Health and Trauma, Neurodegenerative Diseases, Infectious Diseases, CNS Cancer, Others) By Route of Administration (Oral, Parenteral, Others) By End Users (Hospitals, Clinics, Diagnostic Laboratories, Others) By Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) By Region, Competition Forecast & Opportunities, 2026”, the Global Central nervous system therapeutics is expected to grow at a promising rate during the forecast period. Competitive landscape of the market has involved themselves for the advanced research and development of the drugs for central nervous system disorders. The advanced drugs are a major factor for the growth of the market. Moreover, government and FDI are taking initiatives to create awareness about the availability of the effective treatment plans for the CNS disorders thereby supporting the growth of the market.

Due to the onset of COVID-19 and imposition of complete lockdown to mitigate the coronavirus, there has been shutdown of many manufacturing units and disruption in the supply chain resulting in interrupted production and lesser supply of the implants all around the globe. Also, the economy has been adversely affected in many countries resulting in the hinderance to the growth of the Central nervous system therapeutics market. However, after relief from lockdown market is again going to pick up pace to grow significantly.

Browse over XX market data Figures spread through 110 Pages and an in-depth TOC on "Global Central Nervous System Therapeutics Market"

https://www.techsciresearch.com/report/central-nervous-system-therapeutics-market/7322.html

The global central nervous system therapeutics market is segmented by drug class, application, route of administration, end user, distribution channels, and regional distribution. Based on end user the market is further fragmented into hospitals, clinics, diagnostic laboratories, and others. Central nervous system disorder involves diseases like Alzheimer’s, Parkinson’s, Epilepsy, Meningitis, etc. These disorders require advanced treatments that can be taken done in hospitals, thereby justifying the dominance of the segment over market.

Some of the major competitors in the market are Eli Lilly and Company Ltd., Merck & Co. Inc., AstraZeneca PLC, Novartis AG, Teva Pharmaceutical Industries Ltd., F. Hoffmann-La Roche AG, Biogen Inc., Pfizer Inc., GlaxoSmithKline PLC, Otsuka Holdings Co. Ltd., Johnson & Johnson Services Inc., Sanofi SA, Bristol Myers Squibb Pharmaceuticals Ltd., Bayer AG, Amgen Inc., among others. The companies are focusing on extensive research and developments activities to stay competitive in the market. Other competitive strategies include formation of alliances and partnerships.

Download Sample Report @ https://www.techsciresearch.com/sample-report.aspx?cid=7322

Customers can also request for 10% free customization on this report.

“North American region is the most promising landscape for the future investments. Increasing number of depression and anxiety cases in the region approves the theory of exponential market growth in the region. Since the effective medication and treatment is now feasible and available, the market will grow exponentially and invite governmental support too,” said Mr. Karan Chechi, Research Director with TechSci Research, a research based Global management consulting firm.

“Global Central Nervous System Therapeutics Market By Drug Class (Analgesics, Anesthetics, Anticonvulsants, Antiepileptics, Anti-Parkinson Agents, Others) By Application (Neurovascular Diseases, Mental Health and Trauma, Neurodegenerative Diseases, Infectious Diseases, CNS Cancer, Others) By Route of Administration (Oral, Parenteral, Others) By End Users (Hospitals, Clinics, Diagnostic Laboratories, Others) By Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) By Region, Competition Forecast & Opportunities, 2026”, has evaluated the future growth potential of Global Central nervous system therapeutics and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in Global Central nervous system therapeutics.

Browse Related Reports:

Global Pharmaceutical & Biopharmaceutical Contract Manufacturing Market By Sector (Pharmaceutical, Biopharmaceutical), By Product Type (Active Pharmaceutical Ingredients (API), Finished Dosage Formulation (Tablet, Capsule, Oral Liquids, Parenteral/Injectables, Others), Advanced Drug Delivery Products, Over the Counter (OTC) Medicines, Others), By Service (Pharmaceutical Manufacturing Services (Pharmaceutical API Manufacturing Services, Pharmaceutical FDF Manufacturing Services), Biologics Manufacturing Services (Biologics FDF Manufacturing Services, Biologics API Manufacturing Services), Drug Development Services), By Drug Type (Originator / Patented, Generics, Biosimilar), By Region, Forecast & Opportunities, 2025

https://www.techsciresearch.com/report/pharmaceutical-biopharmaceutical-contract-manufacturing-market/5053.html

Global Antimalarial Drugs Market By Drug Type (Quinine, Chloroquine, Proguanil, Amodiaquine, Mefloquine, Hydroxychloroquine, Pyrimethamine, Others), By Drug Class (Aryl Aminoalcohol Compounds, Antifolate Compounds, Artemisinin Compounds, Antimicrobials), By Route of Administration (Oral, Powder Inhalation, Intravenous Administration), By Malaria Type (Plasmodium Falciparum, Plasmodium Malariae, Plasmodium Vivax, Plasmodium Ovale, Plasmodium Knowlesi), By Application (Prevention, Treatment of Malaria), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, E-Commerce, Others), By Region, Forecast & Opportunities, 2025

https://www.techsciresearch.com/report/antimalarial-drugs-market/5012.html

Contact

Mr. Ken Mathews

708 Third Avenue,

Manhattan, NY,

New York – 10017

Tel: +1-646-360-1656

Email: sales@techsciresearch.com

Website: https://www.techsciresearch.com/

For More Market Research Blogs Visit: https://techsciblog.com/

[techsciresearch]

Central Nervous System Therapeutics Market to grow at a Significant Rate During the Forecast Period | TechSci Research

Demand for effective therapeutics for treatment of CNS is a driving factor for the growth of Global Central Nervous System Therapeutics Market in forecast period.

According to TechSci Research report, “Global Central Nervous System Therapeutics Market By Drug Class (Analgesics, Anesthetics, Anticonvulsants, Antiepileptics, Anti-Parkinson Agents, Others) By Application (Neurovascular Diseases, Mental Health and Trauma, Neurodegenerative Diseases, Infectious Diseases, CNS Cancer, Others) By Route of Administration (Oral, Parenteral, Others) By End Users (Hospitals, Clinics, Diagnostic Laboratories, Others) By Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) By Region, Competition Forecast & Opportunities, 2026”, the Global Central nervous system therapeutics is expected to grow at a promising rate during the forecast period. Competitive landscape of the market has involved themselves for the advanced research and development of the drugs for central nervous system disorders. The advanced drugs are a major factor for the growth of the market. Moreover, government and FDI are taking initiatives to create awareness about the availability of the effective treatment plans for the CNS disorders thereby supporting the growth of the market.

Due to the onset of COVID-19 and imposition of complete lockdown to mitigate the coronavirus, there has been shutdown of many manufacturing units and disruption in the supply chain resulting in interrupted production and lesser supply of the implants all around the globe. Also, the economy has been adversely affected in many countries resulting in the hinderance to the growth of the Central nervous system therapeutics market. However, after relief from lockdown market is again going to pick up pace to grow significantly.

Browse over XX market data Figures spread through 110 Pages and an in-depth TOC on "Global Central Nervous System Therapeutics Market"

https://www.techsciresearch.com/report/central-nervous-system-therapeutics-market/7322.html

The global central nervous system therapeutics market is segmented by drug class, application, route of administration, end user, distribution channels, and regional distribution. Based on end user the market is further fragmented into hospitals, clinics, diagnostic laboratories, and others. Central nervous system disorder involves diseases like Alzheimer’s, Parkinson’s, Epilepsy, Meningitis, etc. These disorders require advanced treatments that can be taken done in hospitals, thereby justifying the dominance of the segment over market.

Some of the major competitors in the market are Eli Lilly and Company Ltd., Merck & Co. Inc., AstraZeneca PLC, Novartis AG, Teva Pharmaceutical Industries Ltd., F. Hoffmann-La Roche AG, Biogen Inc., Pfizer Inc., GlaxoSmithKline PLC, Otsuka Holdings Co. Ltd., Johnson & Johnson Services Inc., Sanofi SA, Bristol Myers Squibb Pharmaceuticals Ltd., Bayer AG, Amgen Inc., among others. The companies are focusing on extensive research and developments activities to stay competitive in the market. Other competitive strategies include formation of alliances and partnerships.

Download Sample Report @ https://www.techsciresearch.com/sample-report.aspx?cid=7322

Customers can also request for 10% free customization on this report.

“North American region is the most promising landscape for the future investments. Increasing number of depression and anxiety cases in the region approves the theory of exponential market growth in the region. Since the effective medication and treatment is now feasible and available, the market will grow exponentially and invite governmental support too,” said Mr. Karan Chechi, Research Director with TechSci Research, a research based Global management consulting firm.

“Global Central Nervous System Therapeutics Market By Drug Class (Analgesics, Anesthetics, Anticonvulsants, Antiepileptics, Anti-Parkinson Agents, Others) By Application (Neurovascular Diseases, Mental Health and Trauma, Neurodegenerative Diseases, Infectious Diseases, CNS Cancer, Others) By Route of Administration (Oral, Parenteral, Others) By End Users (Hospitals, Clinics, Diagnostic Laboratories, Others) By Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) By Region, Competition Forecast & Opportunities, 2026”, has evaluated the future growth potential of Global Central nervous system therapeutics and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in Global Central nervous system therapeutics.

Browse Related Reports:

Global Pharmaceutical & Biopharmaceutical Contract Manufacturing Market By Sector (Pharmaceutical, Biopharmaceutical), By Product Type (Active Pharmaceutical Ingredients (API), Finished Dosage Formulation (Tablet, Capsule, Oral Liquids, Parenteral/Injectables, Others), Advanced Drug Delivery Products, Over the Counter (OTC) Medicines, Others), By Service (Pharmaceutical Manufacturing Services (Pharmaceutical API Manufacturing Services, Pharmaceutical FDF Manufacturing Services), Biologics Manufacturing Services (Biologics FDF Manufacturing Services, Biologics API Manufacturing Services), Drug Development Services), By Drug Type (Originator / Patented, Generics, Biosimilar), By Region, Forecast & Opportunities, 2025

https://www.techsciresearch.com/report/pharmaceutical-biopharmaceutical-contract-manufacturing-market/5053.html

Global Antimalarial Drugs Market By Drug Type (Quinine, Chloroquine, Proguanil, Amodiaquine, Mefloquine, Hydroxychloroquine, Pyrimethamine, Others), By Drug Class (Aryl Aminoalcohol Compounds, Antifolate Compounds, Artemisinin Compounds, Antimicrobials), By Route of Administration (Oral, Powder Inhalation, Intravenous Administration), By Malaria Type (Plasmodium Falciparum, Plasmodium Malariae, Plasmodium Vivax, Plasmodium Ovale, Plasmodium Knowlesi), By Application (Prevention, Treatment of Malaria), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, E-Commerce, Others), By Region, Forecast & Opportunities, 2025

https://www.techsciresearch.com/report/antimalarial-drugs-market/5012.html

Contact

Mr. Ken Mathews

708 Third Avenue,

Manhattan, NY,

New York – 10017

Tel: +1-646-360-1656

Email: sales@techsciresearch.com

Website: https://www.techsciresearch.com/

For More Market Research Blogs Visit: https://techsciblog.com/

[ridamiable-blog]

🔹𝑷𝒊𝒄𝒕𝒖𝒓𝒆 𝑻𝒂𝒌𝒆𝒏 𝑶𝒏 𝟭𝟲 𝗔𝗽𝗿𝗶𝗹 𝟮𝟬𝟭𝟴🔹 🌟MEDICAL SEMESTER 5 🌟 ▪ A SHORT REVIEW OF SEMESTER 5 So In this Semester, I Studied 4 Module . ➡In🔹𝑰𝑵𝑭𝑬𝑪𝑻𝑰𝑶𝑼𝑺 𝑫𝑰𝑺𝑬𝑨𝑺𝑬, I learned a Basic Overview of ANATOMY 🔻 PHYSIOLOGY🔻BIOCHEMISTRY🔻 PATHOLOGY (MICROBIOLOGY)🔻(Microorganisms Of common Infectious Diseases along with Stool DR, Urine DR, Culture, etc) MEDICINE🔻+ PEDIATRICS🔻(Different Infectious Diseases i-e Malaria, Typhoid, Dengue, Diarrhea, HIV, Worms, and Fungal Infections, etc) PHARMACOLOGY🔻(Anti Microbial, Anti Malarial, Drugs for STDs, HIV and Anti Inflammatory, etc) AND FORENSIC MEDICINE🔻 ➡In 🔹𝑯𝑬𝑴𝑨𝑻𝑶𝑳𝑶𝑮𝒀, I learned a Basic Overview Of its ANATOMY🔻PHYSIOLOGY🔻BIOCHEMISTRY🔻 PATHOLOGY🔻MEDICINE🔻+ PEDIATRICS🔻(Anemias, Bleeding, and Coagulating disorders, Leukemias and Lymphomas, etc) PHARMACOLOGY🔻(Thrombolytic and Fibrinolytic and Immunomodulating, etc) AND FORENSIC MEDICINE 🔻 ➡ In🔹𝑹𝑬𝑺𝑷𝑰𝑹𝑨𝑻𝑶𝑹𝒀, I learned Basic Overview of ANATOMY🔻PHYSIOLOGY🔻BIOCHEMISTRY🔻 PATHOLOGY🔻MEDICINE 🔻+ PEDIATRICS🔻(Including All Basic Respiratory Disorders With Tumors, etc) PHARMACOLOGY🔻(Antihistamines, Antiasthmatic, Antifolate, AntiTB Drugs, Cell Wall, Protein, and Nucleic acid Synthesis Inhibitors, etc)AND FORENSIC MEDICINE 🔻 ➡ In🔹𝑪𝑨𝑹𝑫𝑰𝑶𝑽𝑨𝑺𝑪𝑼𝑳𝑨𝑹, I learned Basic Overview ANATOMY🔻PHYSIOLOGY🔻BIOCHEMISTRY🔻 PATHOLOGY🔻+ MEDICINE🔻 + PEDIATRICS🔻(Including all CVS disorders with Tumors, etc) PHARMACOLOGY🔻(Drugs to Treat Hyperlipidemia, Angina, ACS, Cardiac Failure AntiCoagulation and Anti Arrhythmic Drugs, etc) FORENSIC MEDICINE🔻 . So This Semester was a New thing for me Because It was totally on Diagnosis, Investigations, and Treatment of Various Disorders, in short, all related to Basic Medicine . . . . . #medicalscience #medicalstudent #medicalstudentlife #medicine #medicalschool #excited😍 #studymotivation #study📚 #doctor #futuredoctor #Happy #medicaldoctortobe #medicalproblems #studybreak #studybreaktime #medicalstudy #medicalexam #medicalrotations #clinicalrotations 🌟 (at United Medical & Dental College - umdc) https://www.instagram.com/p/BwxDV8-AVR6/?igshid=juo9ksmnnlfb

[pharmaffiliatesanalytics]

Methotrexate and Its Impurities - Pharmaffiliates

An antimetabolite of the antifolate type, Methotrexate is an chemotherapy drug and used for treating autoimmune diseases like psoriasis, rheumatoid arthritis. It causes life threatening side effects. Reference standards of Methotrexate API,and its pharmacopeial, non pharmacopeial impurities, and stable isotopes are available at Pharmaffiliates.